GeoVax Advances Mpox Vaccine Development Amid WHO's Global Health Emergency Declaration

By Advos

TL;DR

GeoVax's GEO-MVA offers a strategic advantage by providing a scalable, cost-effective U.S.-based alternative to the single-source Mpox vaccine, enhancing national security and global equity.

GEO-MVA utilizes an advanced continuous avian cell line manufacturing process to increase yield, eliminate egg reliance, reduce costs, and enable rapid U.S. deployment.

GEO-MVA development addresses the global Mpox threat by expanding vaccine access, supporting pandemic preparedness, and improving health outcomes worldwide.

Discover how GEO-MVA's innovative manufacturing could revolutionize vaccine production, offering a glimpse into the future of pandemic response.

Found this article helpful?

Share it with your network and spread the knowledge!

GeoVax Advances Mpox Vaccine Development Amid WHO's Global Health Emergency Declaration

The World Health Organization's recent declaration of Mpox as a Public Health Emergency of International Concern underscores the escalating threat posed by the Clade 1 strain of the Mpox virus, now spreading beyond Central Africa to Europe, Asia, and North America. GeoVax Labs, Inc. is addressing this crisis with the development of GEO-MVA, a U.S.-based MVA vaccine for Mpox and smallpox, aiming to diversify the global vaccine supply currently reliant on a single manufacturer.

With Clade 1 Mpox cases confirmed in several U.S. states and viral particles detected in wastewater across the country, the need for an effective and scalable vaccine solution is critical. GeoVax's GEO-MVA, expected to enter clinical trials in 2026, represents a strategic effort to enhance pandemic resilience, offering a cost-effective, scalable alternative that leverages advanced manufacturing processes to increase production yield and eliminate dependency on pathogen-free chicken eggs.

The company's engagement with U.S. federal agencies and selection for a BARDA initiative highlight the importance of GEO-MVA in strengthening national biosecurity and public health readiness. GeoVax's call to accelerate regulatory pathways and expand federal funding reflects the broader implications of this development for global health security, emphasizing the need for preparedness against future outbreaks.

Curated from NewMediaWire

blockchain registration record for this content
Advos

Advos

@advos